2021 Fiscal Year Annual Research Report
Effectiveness of early introduction of ten-valent pneumococcal conjugate vaccine (PCV-10) on reducing pneumococcal bacterial load in the nasopharynx among neonates.
| Project/Area Number |
17K16272
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
ドバデル ビム 長崎大学, 熱帯医学研究所, 准教授 (80761113)
|
|---|
| Project Period (FY) |
2017-04-01 – 2022-03-31
|
| Keywords | pneumococcus / serotypes / PCV10 / children / Nepal |
|---|
| Outline of Annual Research Achievements |
We have successfully enrolled 600 babies and have followed them at the age of 10 weeks (n=585), 14 weeks (n=564), 9 months (n=470), 12 months (n=340), 15 months (n=169). Follow up children at 12 months and 15 months still going on. Till date, 1530 nasopharyngeal samples have been collected. DNA extraction has been started. Material transfer agreement and approval is already taken from Nepal Health Research Council, Kathmandu. DNA will be brought to Nagasaki and will be tested for pneumococcal serotypes, and prevalence of vaccine and non-vaccine serotypes will be determined. Epidemiological and clinical data are being analysed in STATA to estimate the incidence of acute respiratory infections among infants after the introduction of pneumococcal conjugate vaccine in Nepal.
|
